Literature DB >> 25260979

Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation.

Frédéric Schlemmer1, Sylvie Chevret2, Gwenaël Lorillon1, Cédric De Bazelaire3, Régis Peffault de Latour4, Véronique Meignin5, Mauricette Michallet6, Eric Hermet7, Benjamin Wyplosz8, Véronique Houdouin9, Sylvain Marchand-Adam10, Gérard Socié4, Abdellatif Tazi11, Anne Bergeron12.   

Abstract

BACKGROUND: Various late-onset noninfectious pulmonary complications may occur after allogeneic hematopoietic stem cell transplantation (HSCT). Interstitial lung diseases (ILD) are often overlooked, and few data are available.
METHODS: We retrospectively analyzed the clinical features, pulmonary function tests, radiological features and outcomes of allogeneic HSCT recipients who were diagnosed with a noninfectious ILD and were managed in our center between 2001 and 2010.
RESULTS: Forty patients were analyzed. The median time from transplant to ILD was 11.3 months. The donor hematopoietic stem cell source was peripheral blood stem cells in 75% of the cases. Seventy percent of the patients had extra-thoracic chronic graft versus host disease at ILD diagnosis. We identified two lung computed tomography (CT) scan patterns according to the predominance of ground glass opacities or alveolar consolidations. Restrictive ventilatory defect was the main pulmonary function pattern. Lung histology was available for seven patients and showed diffuse alveolar damage, non-specific interstitial pneumonia, organizing pneumonia or lymphoid interstitial pneumonia. Thirty-five patients (87.5%) were treated with systemic steroids. Thirteen patients died (32.5%), 10 of respiratory failure. The median survival rate at 24 months was 61%.
CONCLUSION: This study highlights the existence of noninfectious post-allogeneic HSCT ILD and provides new insights into the characteristics of these illnesses.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bone marrow transplantation; Diffuse alveolar damage; Interstitial lung disease; Lymphoid interstitial pneumonia; Nonspecific interstitial lung pneumonia; Organizing pneumonia

Mesh:

Year:  2014        PMID: 25260979     DOI: 10.1016/j.rmed.2014.09.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  9 in total

1.  Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.

Authors:  Anne Bergeron; Sylvie Chevret; Angela Granata; Patrice Chevallier; Laure Vincent; Anne Huynh; Reza Tabrizi; Hélène Labussiere-Wallet; Marc Bernard; Sylvain Chantepie; Jacques-Olivier Bay; Anne Thiebaut-Bertrand; Sylvain Thepot; Nathalie Contentin; Luc-Matthieu Fornecker; Natacha Maillard; Karine Risso; Ana Berceanu; Didier Blaise; Regis Peffault de La Tour; Jason W Chien; Valérie Coiteux; Gérard Socié
Journal:  JAMA       Date:  2017-08-08       Impact factor: 56.272

Review 2.  Demystifying idiopathic interstitial pneumonia: time for more etiology-focused nomenclature in interstitial lung disease.

Authors:  Nevins W Todd; Sergei P Atamas; Stella E Hines; Irina G Luzina; Nirav G Shah; Edward J Britt; Andrew J Ghio; Jeffrey R Galvin
Journal:  Expert Rev Respir Med       Date:  2022-01-31       Impact factor: 3.772

3.  Late-Onset, Noninfectious Pulmonary Complications following Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Cohort Study of Long-Term Survivors.

Authors:  Ole Henrik Myrdal; Trond Mogens Aaløkken; Phoi Phoi Diep; Ellen Ruud; Lorentz Brinch; Kristian Fosså; Henrik Mangseth; Johny Kongerud; Liv Ingunn Sikkeland; May B Lund
Journal:  Respiration       Date:  2021-12-22       Impact factor: 3.966

Review 4.  A Systematic Review on Pulmonary Complications Secondary to Hematopoietic Stem Cell Transplantation.

Authors:  Alberto Busmail; Sai Sri Penumetcha; Saher Ahluwalia; Rejja Irfan; Sawleha Arshi Khan; Sai Rohit Reddy; Maria Elisa Vasquez Lopez; Maryam Zahid; Lubna Mohammed
Journal:  Cureus       Date:  2022-05-07

Review 5.  Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis.

Authors:  C Saillard; D Blaise; D Mokart
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

6.  Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation.

Authors:  Yuya Kishida; Naoki Shingai; Konan Hara; Makiko Yomota; Chika Kato; Satoshi Sakai; Yasuhiro Kambara; Yuya Atsuta; Ryosuke Konuma; Atsushi Wada; Daisuke Murakami; Shiori Nakashima; Yusuke Uchibori; Daishi Onai; Atsushi Hamamura; Akihiko Nishijima; Takashi Toya; Hiroaki Shimizu; Yuho Najima; Takeshi Kobayashi; Hisashi Sakamaki; Kazuteru Ohashi; Noriko Doki
Journal:  Sci Rep       Date:  2022-08-19       Impact factor: 4.996

7.  The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease.

Authors:  Yifan Pang; Ananth V Charya; Michael B Keller; Arlene Sirajuddin; Yi-Ping Fu; Noa G Holtzman; Steven Z Pavletic; Sean Agbor-Enoh
Journal:  Blood Adv       Date:  2022-07-26

8.  Pulmonary surveillance in pediatric hematopoietic stem cell transplant: A multinational multidisciplinary survey.

Authors:  Shivanthan Shanthikumar; William A Gower; Matthew Abts; Deborah R Liptzin; Elizabeth K Fiorino; Anne Stone; Saumini Srinivasan; Timothy J Vece; Nour Akil; Theresa Cole; Kenneth R Cooke; Samuel B Goldfarb
Journal:  Cancer Rep (Hoboken)       Date:  2021-07-28

9.  Late-onset noninfectious interstitial lung disease following autologous haematopoietic stem cell transplantation in paediatric patients.

Authors:  Yoon-Kyoung Lee; Rimm Huh; Jihyun Kim; Kangmo Ahn; Ki Woong Sung; Joongbum Cho
Journal:  Respirology       Date:  2016-04-12       Impact factor: 6.424

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.